{"id":"triple-daily-insulin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin is a peptide hormone that binds to insulin receptors on cell surfaces, enabling glucose transport into muscle, fat, and liver cells. By administering insulin three times daily, this regimen mimics the physiological pattern of endogenous insulin secretion to maintain glycemic control throughout the day and reduce postprandial and fasting hyperglycemia.","oneSentence":"Triple-daily insulin replaces or supplements the body's own insulin production to regulate blood glucose levels by facilitating glucose uptake into cells and promoting glycogen synthesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:14:43.059Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus (when oral agents are insufficient)"}]},"trialDetails":[{"nctId":"NCT06274749","phase":"NA","title":"Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial","status":"RECRUITING","sponsor":"National Institute on Aging (NIA)","startDate":"2026-04-01","conditions":"Healthy Volunteer","enrollment":180},{"nctId":"NCT07452913","phase":"PHASE4","title":"Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes","status":"ENROLLING_BY_INVITATION","sponsor":"Bahria University","startDate":"2026-01-01","conditions":"Type 2 Diabetes Mellitus","enrollment":110},{"nctId":"NCT04510506","phase":"NA","title":"Artificial Pancreas - Adolescent Physiology & Psychology Longitudinal Evaluation","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2020-11-19","conditions":"Type 1 Diabetes","enrollment":42},{"nctId":"NCT05404061","phase":"NA","title":"The Poor Responders Study","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2018-08-01","conditions":"Bariatric Surgery Candidate, Obesity, Morbid, Diabetes Mellitus, Type 2","enrollment":220},{"nctId":"NCT06946628","phase":"PHASE3","title":"New Triple Therapy in Newly Diagnosed Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-01","conditions":"Diabetes Mellitus","enrollment":296},{"nctId":"NCT03899402","phase":"PHASE2, PHASE3","title":"Triple Therapy in T1DM","status":"ACTIVE_NOT_RECRUITING","sponsor":"State University of New York at Buffalo","startDate":"2019-05-01","conditions":"Type 1 Diabetes Mellitus","enrollment":78},{"nctId":"NCT05289986","phase":"PHASE4","title":"The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients","status":"TERMINATED","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2023-11-21","conditions":"Hiv","enrollment":18},{"nctId":"NCT03700801","phase":"PHASE4","title":"Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2018-10-01","conditions":"Type 2 Diabetes Mellitus","enrollment":130},{"nctId":"NCT05488223","phase":"NA","title":"Supplementation With PUFA´s in Obese Children","status":"COMPLETED","sponsor":"Hospital Infantil de Mexico Federico Gomez","startDate":"2014-02-17","conditions":"Child Obesity, Insulin Resistance, Metabolic Complication","enrollment":133},{"nctId":"NCT05103306","phase":"","title":"Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy","status":"UNKNOWN","sponsor":"Chungbuk National University Hospital","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT03473262","phase":"","title":"Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Chungbuk National University Hospital","startDate":"2017-01-01","conditions":"Diabetes Mellitus, Type 2","enrollment":200},{"nctId":"NCT03169959","phase":"PHASE1","title":"A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-05-29","conditions":"Type 2 Diabetes Mellitus","enrollment":85},{"nctId":"NCT01770223","phase":"PHASE4","title":"A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-01","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT02758522","phase":"PHASE4","title":"NPH and Regular Insulin in the Treatment of Inpatient Hyperglycemia: Comparison of 3 Basal-bolus Regimens","status":"COMPLETED","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2013-10","conditions":"Diabetes Mellitus, Hyperglycemia","enrollment":105},{"nctId":"NCT00384085","phase":"PHASE4","title":"Insulin Glargine \"All to Target\" Trial","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-05","conditions":"Diabetes Mellitus, Type 2","enrollment":588},{"nctId":"NCT00283049","phase":"PHASE4","title":"Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control","status":"TERMINATED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Diabetes Mellitus, Type 2","enrollment":390}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Triple-daily Insulin","genericName":"Triple-daily Insulin","companyName":"Hospital Universitario Dr. Jose E. Gonzalez","companyId":"hospital-universitario-dr-jose-e-gonzalez","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triple-daily insulin replaces or supplements the body's own insulin production to regulate blood glucose levels by facilitating glucose uptake into cells and promoting glycogen synthesis. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when oral agents are insufficient).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}